Nucleai – Explore the future of AI spatial biomarkers and precision oncology with at ASCO24

Oscar Puig, VP Translational Medicine and Diagnostics at Nucleai, shared a post by Nucleai, on LinkedIn:

“Artificial intelligence is changing the way pathology images are analyzed and scored. There is so much information in those images about the tumor morphology, tumor microenvironment, cell composition, densities and distances. spatial biology digital pathology is improving how patients are treated. Learn more at ASCO24. See you there!!!!”

Quoting Nucleai‘s post:

“ASCO24 kicks off next week! Don’t miss the chance to meet our commercial and strategic team and explore the future of AI spatial biomarkers and precision oncology with us. ”

Additional details.
Source: Oscar Puig/LinkedIn and Nucleai/LinkedIn